The U.S. Food and Drug Administration approved sacituzumab govitecan-hziy, sold as Trodelvy, for first-line treatment of certain breast cancers on June 24, 2026 [4].
This approval provides a critical new option for patients facing triple-negative breast cancer, one of the most aggressive forms of the disease. Because this specific cancer type often lacks the receptors that other treatments target, it typically requires more intensive therapeutic approaches.
The FDA authorized the drug as a first-line monotherapy and for use in combination with pembrolizumab [1]. This approval applies to adults diagnosed with unresectable locally advanced or metastatic triple-negative breast cancer [1].
Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases [1]. The disease is characterized by a significantly lower survival rate compared to other forms of the illness, a disparity that has driven the need for more effective first-line therapies.
Data indicates the five-year survival rate for women with metastatic triple-negative breast cancer is 12% [1]. In contrast, the five-year survival rate for women with other types of metastatic breast cancers is 28% [1].
By expanding the use of Trodelvy to a first-line setting, clinicians can now deploy this therapy earlier in the treatment cycle. This shift aims to improve outcomes for patients who previously had fewer options upon their initial diagnosis of advanced disease.
“Triple-negative breast cancer accounts for about 15% of all breast cancers”
The transition of sacituzumab govitecan-hziy to a first-line treatment represents a strategic shift in oncology. By moving a potent therapy to the start of the treatment regimen, the medical community aims to close the survival gap between triple-negative breast cancer and other metastatic breast cancers, which currently show a survival rate more than double that of the triple-negative variety.
